<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34196889</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1534-6307</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jul</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Current rheumatology reports</Title>
          <ISOAbbreviation>Curr Rheumatol Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Localized Forms of Vasculitis.</ArticleTitle>
        <Pagination>
          <StartPage>49</StartPage>
          <MedlinePgn>49</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">49</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11926-021-01012-y</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE OF REVIEW">To provide an updated review on epidemiology, clinical manifestations, diagnostic assessment, treatment, and prognosis of localized vasculitis, following the 2012 Revised International Chapel Hill Consensus Conference Nomenclature on single-organ vasculitis.</AbstractText>
          <AbstractText Label="RECENT FINDINGS">Localized, single-organ vasculitides encompass a group of rare conditions in which there is no evidence of concomitant systemic vasculitis. Most data on this topic derives from case reports and small case series. Although some aspects of these diseases, such as clinical manifestations and histologic findings, have already been extensively investigated, there is still a lack of robust data concerning the pathogenesis, epidemiology, and treatment. Localized vasculitides may have a wide range of clinical features depending on the organ affected. The inflammatory process may have a multifocal/diffuse or unifocal distribution. Diagnosis is usually based on histopathology findings and exclusion of systemic vasculitis, which may frequently pose a challenge. Further research on treatment is warranted.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Martins-Martinho</LastName>
            <ForeName>Joana</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, 1649-035, Lisbon, Portugal. joanamartinsmartinho@gmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal. joanamartinsmartinho@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dourado</LastName>
            <ForeName>Eduardo</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, 1649-035, Lisbon, Portugal.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Khmelinskii</LastName>
            <ForeName>Nikita</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, 1649-035, Lisbon, Portugal.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Espinosa</LastName>
            <ForeName>Pablo</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Dermatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, 1649-035, Lisbon, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ponte</LastName>
            <ForeName>Cristina</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, 1649-035, Lisbon, Portugal.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Dermatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, 1649-035, Lisbon, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>07</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Curr Rheumatol Rep</MedlineTA>
        <NlmUniqueID>100888970</NlmUniqueID>
        <ISSNLinking>1523-3774</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056647" MajorTopicYN="Y">Systemic Vasculitis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014657" MajorTopicYN="Y">Vasculitis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Cutaneous arteritis</Keyword>
        <Keyword MajorTopicYN="Y">Cutaneous leukocytoclastic angiitis</Keyword>
        <Keyword MajorTopicYN="Y">Isolated aortitis</Keyword>
        <Keyword MajorTopicYN="Y">Single-organ vasculitis</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>1</Day>
          <Hour>12</Hour>
          <Minute>27</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34196889</ArticleId>
        <ArticleId IdType="pmc">PMC8247627</ArticleId>
        <ArticleId IdType="doi">10.1007/s11926-021-01012-y</ArticleId>
        <ArticleId IdType="pii">10.1007/s11926-021-01012-y</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Atisha-Fregoso Y, Hinojosa-Azaola A, Alcocer-Varela J. Localized, single-organ vasculitis: clinical presentation and management. Clin Rheumatol. 2013;32:1–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22918493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hernández-Rodríguez J, Hoffman GS. Updating single-organ vasculitis. Curr Opin Rheumatol. 2012;24:38–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22089096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hernández-Rodríguez J, Molloy ES, Hoffman GS. Single-organ vasculitis. Curr Opin Rheumatol. 2008;20:40–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18281856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CGM, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DGI, Specks U, Stone JH, Takahashi K, Watts RA. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23045170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bolognia JL, editor. Dermatology: ExpertConsult. 3rd ed ff. Edinburgh: Elsevier; 2012.</Citation>
        </Reference>
        <Reference>
          <Citation>Ellis A, Billings SD, Khanna U, Warren CB, Piliang M, Vij A, Ko JS, Bergfeld WF, Fernandez AP. Diagnoses of hospitalized patients with skin abnormalities prompting biopsy by consulting dermatologists: a 3-year review from a tertiary care center. J Cutan Pathol. 2020;47:346–356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31845375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arora A, Wetter DA, Gonzalez-Santiago TM, Davis MDP, Lohse CM. Incidence of leukocytoclastic vasculitis, 1996 to 2010: a population-based study in Olmsted County, Minnesota. Mayo Clin Proc. 2014;89:1515–1524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4252802</ArticleId>
            <ArticleId IdType="pubmed">24981218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carlson JA, Ng BT, Chen K-R. Cutaneous vasculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis. Am J Dermatopathol. 2005;27:504–528.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16314707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen K-R, Carlson JA. Clinical approach to cutaneous vasculitis. Am J Clin Dermatol. 2008;9:71–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18284262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jameson JL, editor. Harrison’s principles of internal medicine. Twentieth. New York: McGraw-Hill Education; 2018. </Citation>
        </Reference>
        <Reference>
          <Citation>Mayor-Ibarguren A, Feito-Rodriguez M, Quintana Castanedo L, Ruiz-Bravo E, Montero Vega D, Herranz-Pinto P. Cutaneous small vessel vasculitis secondary to COVID-19 infection: a case report. J Eur Acad Dermatol Venereol. 2020 [cited 2020 Nov 7];34. Available from: 10.1111/jdv.16670.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7280661</ArticleId>
            <ArticleId IdType="pubmed">32441876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dominguez-Santas M, Diaz-Guimaraens B, Garcia Abellas P, Moreno-Garcia del Real C, Burgos-Blasco P, Suarez-Valle A. Cutaneous small-vessel vasculitis associated with novel 2019 coronavirus SARS-CoV-2 infection (COVID-19). J Eur Acad Dermatol Venereol. 2020 [cited 2020 Nov 7];34. Available from: 10.1111/jdv.16663.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7283648</ArticleId>
            <ArticleId IdType="pubmed">32453865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pastuszczak M, Celińska-Löwenhoff M, Sułowicz J, Wojas-Pelc A, Musiał J. Clinical study on single-organ cutaneous small vessels vasculitis (SoCSVV). Medicine. 2017;96:e6376. This study focuses on characterizing single-organ cutaneous small-vessel vasculitis and identify its precipitating factors and risk of recurrence.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5371464</ArticleId>
            <ArticleId IdType="pubmed">28328827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tai YJ, Chong AH, Williams RA, Cumming S, Kelly RI. Retrospective analysis of adult patients with cutaneous leukocytoclastic vasculitis. Australas J Dermatol. 2006;47:92–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16637802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loricera J, Blanco R, Ortiz-Sanjuan F, Hernandez JL, Pina T, Gonzalez-Vela MC, Calvo-Rio V, Rueda-Gotor J, Alvarez L, Gonzalez-Lopez MA, Marcellan M, Gonzalez-Gay MA. Single-organ cutaneous small-vessel vasculitis according to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides: a study of 60 patients from a series of 766 cutaneous vasculitis cases. Rheumatology. 2015;54:77–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25065012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinez-Taboada MDVM, Blanco MDR, Garcia-Fuentes MDM, Rodriguez-Valverde MDV. Clinical features and outcome of 95 patients with hypersensitivity vasculitis. Am J Med. 1997;102:186–191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9217569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Russell JP, Gibson LE. Primary cutaneous small vessel vasculitis: approach to diagnosis and treatment. Int J Dermatol. 2006;45:3–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16426368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baigrie D, Bansal P, Goyal A, Crane JS. Leukocytoclastic vasculitis. StatPearls. Treasure Island: StatPearls Publishing; 2020 [cited 2020 Nov 1]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK482159/.</Citation>
        </Reference>
        <Reference>
          <Citation>Micheletti RG. Cutaneous vasculitis in rheumatologic disease: Current concepts of skin and systemic manifestations. Clin Dermatol. 2018;36:561–566.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30047438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wick MR, Patterson JW. Cutaneous paraneoplastic syndromes. Semin Diagn Pathol. 2019;36:211–228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30736994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leavitt RY, Fauci AS. Polyangiitis overlap syndrome. Am J Med. 1986;81:79–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2873744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weng C-H, Liu Z-C. Drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. Chin Med J. 2019;132:2848–2855.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6940077</ArticleId>
            <ArticleId IdType="pubmed">31856057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carlson JA, Cavaliere LF, Grant-Kels JM. Cutaneous vasculitis: diagnosis and management. Clin Dermatol. 2006;24:414–429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16966021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chango Azanza JJ, Calle Sarmiento PM, Lopetegui Lia N, Alexander SA, Modi V. Leukocytoclastic vasculitis: an early skin biopsy makes a difference. Cureus. 2020;12(5):e7912. doi: 10.7759/cureus.7912.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7759/cureus.7912</ArticleId>
            <ArticleId IdType="pmc">PMC7263727</ArticleId>
            <ArticleId IdType="pubmed">32494527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carlson JA. The histological assessment of cutaneous vasculitis. Histopathology. 2010;56:3–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20055902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang Y, Park J, Ha Y-J, Kang M, Park H-J, Lee S-W, Lee SK, Park YB. Differences in clinical manifestations and outcomes between adult and child patients with Henoch-Schönlein purpura. J Korean Med Sci. 2014;29:198–203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3923997</ArticleId>
            <ArticleId IdType="pubmed">24550645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chhabra S, Singh S, Radotra B, Kumar B, Minz R. Direct immunofluorescence of skin biopsy: perspective of an immunopathologist. Indian J Dermatol Venereol Leprol. 2010;76:150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20228544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Micheletti RG, Pagnoux C. Management of cutaneous vasculitis. Presse Med. 2020;49:104033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32645416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sais G, Vidaller A, Jucglà A, Servitje O, Condom E, Peyrí J. Prognostic factors in leukocytoclastic vasculitis: a clinicopathologic study of 160 patients. Arch Dermatol. 1998;134:309–315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9521029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Callen JP, af Ekenstam E. Cutaneous leukocytoclastic vasculitis: clinical experience in 44 patients. South Med J. 1987;80:848–851.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3603105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sais G, Vidaller A, Jucglà A, Gallardo F, Peyrí J. Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Arch Dermatol. 1995;131:1399–1402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7492128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cribier B, Cuny JF, Schubert B, Colson A, Truchetet F, Crosshans E. Recurrent annular erythema with purpura: a new variant of leucocytoclastic vasculitis responsive to dapsone. Br J Dermatol. 1996;135:972–975.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8977722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruiz Villaverde R, Blasco Melguizo J, Martin Sanchez M, Naranjo SR. Annular leucocytoclastic vasculitis: response to dapsone. J Eur Acad Dermatol Venerol. 2002;16:544–546.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12428865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seybold H, Simon M, Schuler G, Lüftl M. Therapierefraktäre kutane nekrotisierende Vaskulitis: Erfolgreiche Sulfontherapie. Hautarzt. 2006;57:47–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15662534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Callen JP. Azathioprine. An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol. 1991;127:515–522.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2006876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Espinoza LR, Espinoza CG, Vasey FB, Germain BF. Oral methotrexate therapy for chronic rheumatoid arthritis ulcerations. J Am Acad Dermatol. 1986;15:508–512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3760277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Upchurch KS, Heller K, Bress NM. Low-dose methotrexate therapy for cutaneous vasculitis of rheumatoid arthritis. J Am Acad Dermatol. 1987;17:355–359.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3624579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams HC, Pembroke AC. Methotrexate in the treatment of vasculitic cutaneous ulceration in rheumatoid arthritis. J R Soc Med. 1989;82:763.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1292427</ArticleId>
            <ArticleId IdType="pubmed">2614773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lopez L, Davis K, Kohler P, Schocket A. The hypocomplementemic urticarial-vasculitis syndrome: therapeutic response to hydroxychloroquine. J Allergy Clin Immunol. 1984;73:600–603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6371104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melamed J, Laznickova H. Combination therapy with dapsone, colchicine and hydroxychloroquine in the treatment of urticarial vasculitis. J Allergy Clin Immunol. 2007;119:S204.</Citation>
        </Reference>
        <Reference>
          <Citation>Haeberle MT, Adams WB, Callen JP. Treatment of severe cutaneous small-vessel vasculitis with mycophenolate mofetil. Arch Dermatol. 2012;148:887–888.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22911181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Worm M, Sterry W, Kolde G. Mycophenolate mofetil is effective for maintenance therapy of hypocomplementaemic urticarial vasculitis. Br J Dermatol. 2000;143:1324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11122046</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nikibakhsh AA, Mahmoodzadeh H, Karamyyar M, Hejazi S, Noroozi M, Macooie AA, Gholizadeh A, Gholizadeh L. Treatment of complicated Henoch-Schönlein purpura with mycophenolate mofetil: a retrospective case series report. Int J Rheumatol. 2010;2010:1–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2901604</ArticleId>
            <ArticleId IdType="pubmed">20628492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swaminath A, Magro CM, Dwyer E. Refractory urticarial vasculitis as a complication of ulcerative colitis successfully treated with rituximab. J Clin Rheumatol. 2011;17:281–283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21778903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Reshaid K, Madda JP. Rituximab Therapy for severe cutaneous leukocytoclastic angiitis refractory to corticosteroids, Cellcept and cyclophosphamide. Case Rep Dermatol. 2013;5:115–119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3656690</ArticleId>
            <ArticleId IdType="pubmed">23687489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu PY, Prete PE, Kukes G. Leukocytoclastic Vasculitis in a patient with type 1 cryoglobulinemia. Case Rep Rheumatol. 2011;2011:1–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3420475</ArticleId>
            <ArticleId IdType="pubmed">22937435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mang R, Ruzicka T, Stege H. Therapy for severe necrotizing vasculitis with infliximab. J Am Acad Dermatol. 2004;51:321–322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15280860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ong CS, Benson EM. Successful treatment of chronic leucocytoclastic vasculitis and persistent ulceration with intravenous immunoglobulin. Br J Dermatol. 2000;143:447–449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10951164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stratigos J, Katsambas A, Potouridou E. Cyclosporin: a therapy for allergic cutaneous vasculitis with multiple recurrences. J Dermatol Treat. 1994;5:93–95.</Citation>
        </Reference>
        <Reference>
          <Citation>Tosca AD, Ioannidou DJ, Katsantonis JC, Kyriakis KP. Cyclosporin A in the treatment of cutaneous vasculitis. Clinical and cellular effects. J Eur Acad Dermatol Venerol. 1996;6:135–141.</Citation>
        </Reference>
        <Reference>
          <Citation>Bezerra AS, Polimanti AC, de Oliveira RA, Fürst RV d C, Criado PR, Corrêa JA. Diagnóstico e terapêutica precoce de vasculite leucocitoclástica: relato de caso. J Vasc Bras. 2020;19:e20180072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6956624</ArticleId>
            <ArticleId IdType="pubmed">31975988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindberg K. Ein Beitrag zur Kenntnis der Periarteriitis nodosa. Acta Med Scand. 1931;76:183–225.</Citation>
        </Reference>
        <Reference>
          <Citation>Herbert CR, Russo GG. Polyarteritis nodosa and cutaneous polyarteritis nodosa. Skinmed. 2003 Sep-Oct;2(5):277–83; quiz 284-5. 10.1111/j.1540-9740.2003.02214.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14673260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chasset F, Francès C. Cutaneous manifestations of medium- and large-vessel vasculitis. Clin Rev Allergy Immunol. 2017;53:452–468.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28547523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daoud M, Hutton K, Gibson L. Cutaneous periarteritis nodosa: a clinicopathological study of 79 cases. Br J Dermatol. 1997;136:706–713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9205503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bansal N-K, Houghton KM. Cutaneous polyarteritis nodosa in childhood: a case report and review of the literature. Arthritis. 2010;2010:1–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3200074</ArticleId>
            <ArticleId IdType="pubmed">22046510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Munera-Campos M, Bielsa I, Martínez-Morillo M, Aparicio G, Olivé A, Ferrándiz C. Manifestations, clinical course and prognostic markers in cutaneous polyarteritis nodosa. J Dtsch Dermatol Ges. 2020;18(11):1250–1259. doi: 10.1111/ddg.14271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ddg.14271</ArticleId>
            <ArticleId IdType="pubmed">33015940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Criado PR, Marques GF, Morita TCAB, de Carvalho JF. Epidemiological, clinical and laboratory profiles of cutaneous polyarteritis nodosa patients: report of 22 cases and literature review. Autoimmun Rev. 2016;15:558–563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26876385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alibaz-Oner F, Koster MJ, Crowson CS, Makol A, Ytterberg SR, Salvarani C, Matteson EL, Warrington KJ. Clinical spectrum of medium-sized vessel vasculitis: medium-sized vessel vasculitis. Arthritis Care Res. 2017;69:884–891.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27564269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diaz-Perez JL, Schroeter AL, Winkelmann RK. Cutaneous periarteritis nodosa: immunofluorescence studies. Arch Dermatol. 1980;116(1):56–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6101533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawakami T, Yamazaki M, Mizoguchi M, Soma Y. High titer of anti–phosphatidylserine-prothrombin complex antibodies in patients with cutaneous polyarteritis nodosa. Arthritis Rheum. 2007;57:1507–1513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18050170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Till SH, Amos RS. Long-term follow-up of juvenile-onset cutaneous polyarteritis nodosa associated with streptococcal infection. Rheumatology. 1997;36:909–911.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9291862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoue N, Shimizu M, Mizuta M, Ikawa Y, Yachie A. Refractory cutaneous polyarteritis nodosa: successful treatment with etanercept. Pediatr Int. 2017;59:751–752.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28626974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Breda L, Franchini S, Marzetti V, Chiarelli F. Intravenous immunoglobulins for cutaneous polyarteritis nodosa resistant to conventional treatment. Scand J Rheumatol. 2016;45:169–170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26526030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morgan AJ, Schwartz RA. Cutaneous polyarteritis nodosa: a comprehensive review: cutaneous polyarteritis nodosa. Int J Dermatol. 2010;49:750–756.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20618492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Culver B, Itkin A, Pischel K. Case report and review of minocycline-induced cutaneous polyarteritis nodosa. Arthritis Rheum. 2005;53:468–470.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15934105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Padeh S, Zlotogorski A, Berkun Y, Press JJ, Mukamel M, Voth I, Hashkes PJ, Harel L, Hoffer V, Ling E, Yalcinkaya F, Kasapcopur O, Lee MK, Klevit RE, Renbaum P, Weinberg-Shukron A, Sener EF, Schormair B, Zeligson S, Marek-Yagel D, Strom TM, Shohat M, Singer A, Rubinow A, Pras E, Winkelmann J, Tekin M, Anikster Y, King MC, Levy-Lahad E. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med. 2014;370:921–931.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24552285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonzalez Santiago TM, Zavialov A, Saarela J, Seppanen M, Reed AM, Abraham RS, Gibson LE. Dermatologic features of ADA2 deficiency in cutaneous polyarteritis nodosa. JAMA Dermatol. 2015;151:1230–1234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26131734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen K-R. Cutaneous Polyarteritis nodosa: a clinical and histopathological study of 20 cases. J Dermatol. 1989;16:429–442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2576427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borrie P. Cutaneous polyarteritis nodosa. Br J Dermatol. 1972;87:87–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4403497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moreland LW, Ball GV. Cutaneous polyarteritis nodosa. Am J Med. 1990;88(4):426–430. doi: 10.1016/0002-9343(90)90502-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0002-9343(90)90502-5</ArticleId>
            <ArticleId IdType="pubmed">1970223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bauza A, Espana A, Idoate M. Cutaneous polyarteritis nodosa. Br J Dermatol. 2002;146:694–699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11966708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rogalski C, Sticherling M. Panarteritis cutanea benigna ? An entity limited to the skin or cutaneous presentation of a systemic necrotizing vasculitis? Report of seven cases and review of the literature. Int J Dermatol. 2007;46:817–821.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17651163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kint N, De Haes P, Blockmans D. Comparison between classical polyarteritis nodosa and single organ vasculitis of medium-sized vessels: a retrospective study of 25 patients and review of the literature. Acta Clin Belg. 2016;71:26–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25560060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi SW, Lew S, Cho SD, Cha HJ, Eum E-A, Jung HC, et al.  Cutaneous polyarteritis nodosa presented with digital gangrene: a case report. J Korean Med Sci. 2006;21:371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2734024</ArticleId>
            <ArticleId IdType="pubmed">16614534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stussi G, Schneider E, Trüeb RM, Seebach JD. Acral necrosis of the fingers as initial manifestation of cutaneous polyarteritis nodosa--a case report. Angiology. 2001;52(1):63–67. doi: 10.1177/000331970105200109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/000331970105200109</ArticleId>
            <ArticleId IdType="pubmed">11205933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morimoto A, Chen K-R. Reappraisal of histopathology of cutaneous polyarteritis nodosa: reappraisal of histopathology of C-PAN. J Cutan Pathol. 2016;43:1131–1138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27592619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamura T, Kanazawa N, Ikeda T, Yamamoto Y, Nakabayashi K, Ozaki S, Furukawa F. Cutaneous polyarteritis nodosa: revisiting its definition and diagnostic criteria. Arch Dermatol Res. 2009;301:117–121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18802715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Do N, Ringold S, Brandling-Bennett H. Cutaneous polyarteritis nodosa in pediatric patients successfully treated with TNF-α inhibitor and methotrexate: case series and literature review. Pediatr Dermatol. 2019;36:932–935.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31576593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shirai T, Shirota Y, Fujii H, Ishii T, Harigae H. Four distinct clinical phenotypes of vasculitis affecting medium-sized arteries. Scand J Rheumatol. 2019;48:308–14. This is a retrospective study that divides CPAN patients into four categories according to disease severity and compares clinical manifestations, treatment and outcomes.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30672367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schartz NEC, Alaoui S, Vignon-Pennamen MD, Cordoliani F, Fermand JP, Morel P, Rybojad M. Successful treatment in two cases of steroid-dependent cutaneous polyarteritis nodosa with low-dose methotrexate. Dermatology. 2001;203:336–338.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11752825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Subbanna PK, Swaminathan R, Singh N. Cutaneous polyarteritis nodosa: a rare isolated cutaneous vasculitis. Indian Dermatol Online J. 2012;3:21–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3481924</ArticleId>
            <ArticleId IdType="pubmed">23130255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hernández-Rodríguez J, Alba MA, Prieto-González S, Cid MC. Diagnosis and classification of polyarteritis nodosa. J Autoimmun. 2014;48–49:84–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24485157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Virgilio A, Greco A, Magliulo G, Gallo A, Ruoppolo G, Conte M, et al.  Polyarteritis nodosa: a contemporary overview. Autoimmun Rev. 2016;15:564–570.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26884100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Le Guern V, et al.  Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French vasculitis study group database. Arthritis Rheum. 2010;62:616–626.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20112401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dutra LA, de Souza AWS, Grinberg-Dias G, Barsottini OGP, Appenzeller S. Central nervous system vasculitis in adults: an update. Autoimmun Rev. 2017;16:123–131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28087351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byram K, Hajj-Ali RA, Calabrese L. CNS vasculitis: an approach to differential diagnosis and management. Curr Rheumatol Rep. 2018;20:37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29846828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cinar I, Wang H, Stone JR. Clinically isolated aortitis: pitfalls, progress, and possibilities. Cardiovasc Pathol. 2017;29:23–32. The authors give a detailed and updated overview on the epidemiology, pathology, etiology, management, and long-term outcomes of patients with clinically isolated aortitis.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28500877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aghayev A, Bay CP, Tedeschi S, et al.  Clinically isolated aortitis: imaging features and clinical outcomes: comparison with giant cell arteritis and giant cell aortitis. The International Journal of Cardiovascular Imaging. 2021;37(4):1433–1443. doi: 10.1007/s10554-020-02087-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10554-020-02087-x</ArticleId>
            <ArticleId IdType="pubmed">33128155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gornik HL, Creager MA. Aortitis. Circulation. 2008;117:3039–3051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2759760</ArticleId>
            <ArticleId IdType="pubmed">18541754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stone JR, Bruneval P, Angelini A, Bartoloni G, Basso C, Batoroeva L, Buja LM, Butany J, d'Amati G, Fallon JT, Gittenberger-de Groot AC, Gouveia RH, Halushka MK, Kelly KL, Kholova I, Leone O, Litovsky SH, Maleszewski JJ, Miller DV, Mitchell RN, Preston SD, Pucci A, Radio SJ, Rodriguez ER, Sheppard MN, Suvarna SK, Tan CD, Thiene G, van der Wal AC, Veinot JP. Consensus statement on surgical pathology of the aorta from the Society for Cardiovascular Pathology and the Association for European Cardiovascular Pathology: I. Inflammatory diseases. Cardiovasc Pathol. 2015;24:267–278.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26051917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marvisi C, Accorsi Buttini E, Vaglio A. Aortitis and periaortitis: the puzzling spectrum of inflammatory aortic diseases. Presse Med. 2020;49:104018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32234379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Espitia O, Samson M, Le Gallou T, Connault J, Landron C, Lavigne C, et al.  Comparison of idiopathic (isolated) aortitis and giant cell arteritis-related aortitis. A French retrospective multicenter study of 117 patients. Autoimmun Rev. 2016;15:571–576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26903476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loricera J, Blanco R, Hernández JL, Carril JM, Martínez-Rodríguez I, Canga A, et al.  Non-infectious aortitis: a report of 32 cases from a single tertiary centre in a 4-year period and literature review. Clin Exp Rheumatol. 2015;33:S-19–S-31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25437450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller DV, Isotalo PA, Weyand CM, Edwards WD, Aubry M-C, Tazelaar HD. Surgical pathology of noninfectious ascending aortitis: a study of 45 cases with emphasis on an isolated variant. Am J Surg Pathol. 2006;30:9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16931960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Smith RN, Spooner AE, Isselbacher EM, Cambria RP, MacGillivray TE, et al.  Giant cell aortitis of the ascending aorta without signs or symptoms of systemic vasculitis is associated with elevated risk of distal aortic events. Arthritis Rheum. 2012;64:317–319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21953530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Svensson LG, Arafat A, Roselli EE, Idrees J, Clifford A, Tan C, Hoffman G, Eng C, Langford C, Rodriguez ER, Gornik HL, Blackstone E, Sabik JF, III, Lytle BW. Inflammatory disease of the aorta: patterns and classification of giant cell aortitis, Takayasu arteritis, and nonsyndromic aortitis. J Thorac Cardiovasc Surg. 2015;149:S170–S175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25218529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferfar Y, Morinet S, Espitia O, Agard C, Vautier M, Comarmond C, Desbois AC, Domont F, Fouret PJ, Redheuil A, Cluzel P, Chiche L, Koskas F, Resche-Rigon M, Cacoub P, Biard L, Saadoun D, For the French Study Group for Large Vessel Vasculitis (GEFA)  Long-term outcome and prognosis factors of isolated aortitis. Circulation. 2020;142:92–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32628555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maritati F, Corradi D, Versari A, Casali M, Urban ML, Buzio C, Vaglio A. Rituximab therapy for chronic periaortitis. Ann Rheum Dis. 2012;71:1262–1264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22586161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, Deshpande V, Smyrk TC, Chari S, Stone JH. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74:1171–1177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25667206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hernández-Rodríguez J, Tan CD, Molloy ES, Khasnis A, Rodríguez ER, Hoffman GS. Vasculitis involving the breast: a clinical and histopathologic analysis of 34 patients. Medicine. 2008;87:61–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18344804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hernández-Rodríguez J, Tan CD, Koening CL, Khasnis A, Rodríguez ER, Hoffman GS. Testicular Vasculitis: findings differentiating isolated disease from systemic disease in 72 patients. Medicine. 2012;91:75–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22391469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hernández-Rodríguez J, Tan CD, Rodríguez ER, Hoffman GS. Gynecologic vasculitis: an analysis of 163 patients. Medicine (Baltimore). 2009;88(3):169–181. doi: 10.1097/MD.0b013e3181a577f3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0b013e3181a577f3</ArticleId>
            <ArticleId IdType="pubmed">19440120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bastone P, Squifflet JL, Marbaix E, Houssiau F. Successful treatment of gynaecological involvement of granulomatosis with polyangiitis (Wegener's granulomatosis) by rituximab. Clin Exp Rheumatol. 2015;33(2 Suppl 89):S-142–S-144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26016766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tabbarah A, Voltaggio L. Giant cell arteritis of the breast. Arch Pathol Lab Med. 2017;141:1283–1287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28854344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren J, Liu J, Su J, Zhang J, Zhao J. Systemic vasculitis involving the breast: a case report and literature review. Rheumatol Int. 2019;39:1447–1455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30874872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roma AA, Amador-Ortiz C, Liapis H. Significance of isolated vasculitis in the gynecological tract: what clinicians do with the pathologic diagnosis of vasculitis? Ann Diagn Pathol. 2014;18:199–202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24846840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brimo F, Lachapelle J, Epstein JI. Testicular Vasculitis: a series of 19 cases. Urology. 2011;77:1043–1048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21419476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pagnoux C, Mahr A, Cohen P, Guillevin L. Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine. 2005;84:115–128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15758841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salvarani C, Calamia KT, Crowson CS, Miller DV, Broadwell AW, Hunder GG, Matteson EL, Warrington KJ. Localized vasculitis of the gastrointestinal tract: a case series. Rheumatology. 2010;49:1326–1335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20360040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burke AP, Sobin LH, Virmani R. Localized vasculitis of the gastrointestinal tract. Am J Surg Pathol. 1995;19:338–349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7872432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collins MP, Dyck PJB, Gronseth GS, Guillevin L, Hadden RDM, Heuss D, Léger JM, Notermans NC, Pollard JD, Said G, Sobue G, Vrancken AF, Kissel JT, Peripheral Nerve Society  Peripheral Nerve Society Guideline* on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. J Peripher Nerv Syst. 2010;15:176–184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21040139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graf J, Imboden J. Vasculitis and peripheral neuropathy. Curr Opin Rheumatol. 2019;31:40–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30461543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collins MP, Hadden RD. The nonsystemic vasculitic neuropathies. Nat Rev Neurol. 2017;13:302–316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28447661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collins MP, Arnold WD, Kissel JT. The neuropathies of vasculitis. Neurol Clin. 2013;31:557–595.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23642724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hadden RDM, Collins MP, Živković SA, Hsieh S-T, Bonetto C, Felicetti P, Marchione P, Santuccio C, Bonhoeffer J, Brighton Collaboration Vasculitic Peripheral Neuropathy Working Group  Vasculitic peripheral neuropathy: case definition and guidelines for collection, analysis, and presentation of immunisation safety data. Vaccine. 2017;35:1567–1578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26655629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones RB, Tervaert JWC, Hauser T, Luqmani R, Morgan MD, Peh CA, et al.  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211–220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20647198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis. New Engl J Med. 2010;363:221–232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3137658</ArticleId>
            <ArticleId IdType="pubmed">20647199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Üçeyler N, Geng A, Reiners K, Toyka KV, Sommer C. Non-systemic vasculitic neuropathy: single-center follow-up of 60 patients. J Neurol. 2015;262:2092–2100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26092519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collins MP, Periquet MI, Mendell JR, Sahenk Z, Nagaraja HN, Kissel JT. Nonsystemic vasculitic neuropathy: insights from a clinical cohort. Neurology. 2003;61:623–630.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12963752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pourafshar N, Sobel E, Segal M. A case of isolated renal involvement of polyarteritis nodosa successfully treated with steroid monotherapy. BMJ Case Rep. 2016. 10.1136/bcr-2016-215702.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4964193</ArticleId>
            <ArticleId IdType="pubmed">27440849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watanabe R, Nakaya I, Kudo H, Yahata M, Sakuma T, Soma J. Isolated granulomatous renal arteritis: a variant form of giant cell arteritis with few macrophages. Intern Med. 2010;49(2):191–194. doi: 10.2169/internalmedicine.49.2480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2169/internalmedicine.49.2480</ArticleId>
            <ArticleId IdType="pubmed">20075589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gigante A, Salviani C, Giannakakis K, Rosato E, Barbano B, Moroso A, Gasperini ML, Nofroni I, Salsano F, Cianci R, Pugliese F. Clinical and histological outcome predictors in renal limited pauci-immune crescentic glomerulonephritis: a single centre experience. Int J Immunopathol Pharmacol. 2012;25(1):287–292. doi: 10.1177/039463201202500133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/039463201202500133</ArticleId>
            <ArticleId IdType="pubmed">22507343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weidner S, Geuss S, Hafezi-Rachti S, Wonka A, Rupprecht HD. ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant. 2004;19:1403–1411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15069175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Asrar AMA, Herbort CP, Tabbara KF. A clinical approach to the diagnosis of retinal vasculitis. Int Ophthalmol. 2010;30:149–173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19190857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khellaf M, Hamidou M, Pagnoux C, Michel M, Brisseau JM, Chevallier X, Cohen P, Guillevin L, Godeau B. Vasculitis restricted to the lower limbs: a clinical and histopathological study. Ann Rheum Dis. 2007;66:554–556.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1856040</ArticleId>
            <ArticleId IdType="pubmed">17068062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parsa P, Rios A, Anderson LN, Eidt JF, Gable D, Grimsley B. Isolated lower extremity vasculitis leading to progressive critical limb ischemia. J Vasc Surg Cases Innov Tech. 2017;3:119–122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5764861</ArticleId>
            <ArticleId IdType="pubmed">29349396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ojima Y, Sawada K, Fujii H, Shirai T, Saito A, Kagaya S, Aoki S, Takeuchi Y, Ishii T, Nagasawa T. Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) restricted to the limbs. Intern Med. 2018;57:1301–1308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5980815</ArticleId>
            <ArticleId IdType="pubmed">29279515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamimura T, Hatakeyama M, Torigoe K, Nara H, Kaneko N, Satou H, Yoshio T, Okazaki H, Minota S. Muscular polyarteritis nodosa as a cause of fever of undetermined origin: a case report and review of the literature. Rheumatol Int. 2005;25:394–397.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15965639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balbir-Gurman A, Nahir AM, Braun-Moscovici Y. Intravenous immunoglobulins in polyarteritis nodosa restricted to the limbs: case reports and review of the literature. Clin Exp Rheumatol. 2007;25:S28–S30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17428360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>García F, Pedrol E, Casademont J, Mellado B, Córdoba R, Cid M, Grau JM. Polyarteritis nodosa confined to calf muscles. J Rheumatol. 1992;19:303–305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1352825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carreon CK, Esposito MJ. Eosinophilic coronary monoarteritis. Arch Pathol Lab Med. 2014;138:979–981.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24978927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arena V, Valerio L, Arena E, De-Giorgio F, Stigliano E, Monego G, et al.  Isolated eosinophilic coronary arteritis. J Clin Pathol. 2010;63:469–471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20360142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stoukas V, Dragovic LJ. Sudden deaths from eosinophilic coronary monoarteritis: a subset of spontaneous coronary artery dissection. Am J Forensic Med Pathol. 2009;30:268–269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19696583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujita K, Kasama S, Kurabayashi M. Pitfalls in the management of isolated pulmonary Takayasu’s arteritis after surgery: a case report of an experience during 34 months after a pulmonary artery graft replacement. J Cardiothorac Surg. 2016;11:7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4715312</ArticleId>
            <ArticleId IdType="pubmed">26772757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamazaki I, Ichikawa Y, Ishii M, Hamada T, Kajiwara H. Surgical case of isolated pulmonary Takayasu’s arteritis. Circ J. 2005;69:500–502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15791050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alizadehasl A, Saedi S, Ganji H, Pourafkari L. Isolated peripheral pulmonary stenosis in Takayasu arteritis. Int J Rheum Dis. 2020;23:116–119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31746147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y-H, Song W-M, Wu M, Zhu J. Initial isolated Takayasu’s arteritis of bilateral pulmonary artery branches. Rev Bras Reumatol Engl Ed. 2017;57:626–629.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29173701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukuda Y, Shirai K, Takamiya Y, Nathan M, Mito T, Yamagi D, Hida S, Iwata A, Yasuda T, Zang B, Nishikawa H, Ideishi M, Saku K. Isolated pulmonary arterial stenosis caused by Takayasu’s arteritis in an elderly male. J Cardiol. 2008;51:196–200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18522795</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
